Dirucotide

Drug Profile

Dirucotide

Alternative Names: MBP 8298; SF328

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AutoImmune; University of Alberta
  • Developer BioMS Medical Corporation
  • Class Peptides
  • Mechanism of Action Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 06 Jul 2010 BioMS Medical is now called Medwell Capital Corp.
  • 02 Sep 2009 BioMS Medical and Eli Lilly terminate their collaboration for dirucotide
  • 06 Oct 2008 BioMS receives a sixth positive review from the independent Data Safety Monitoring Board (DSMB) for the ongoing MINDSET-01 trial in relapsing-remitting Multiple sclerosis in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top